Global healthcare company Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China, to primarily develop innovative therapeutics through biomedical research and development (R&D).

Sinovant is also backed by Chinese private equity firm CITICPE.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sinovant has a pipeline of 11 investigational drugs intended for Greater China and other Asian markets. The newest additions to the pipeline are derazantinib, lefamulin and RVT-802.

The formation of the pipeline, as well as the creation of a senior leadership team, was the result of Roivant’s support.

Derazantinib is an inhibitor of fibroblast growth factor receptor (FGFR) and is currently in Phase III clinical development to treat intrahepatic cholangiocarcinoma (iCCA), a type of liver cancer with high incidence in Greater China that has no approved therapies.

Lefamulin is an antibiotic, which is expected to offer a first-line empiric monotherapy for community-acquired bacterial pneumonia (CABP) because of its low incidence of cross-resistance and low susceptibility to develop bacterial resistance.

“Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China to primarily develop innovative therapeutics.”

The therapeutic already completed assessment in two Phase III trials for the treatment of CABP. It was recently granted qualified infectious disease product designation from the US Food and Drug Administration (FDA) and a new drug application submission is preparing to be launched in the US and Europe.

RVT-802 is a tissue-based regenerative therapy being developed for treating primary immune deficiency caused due to congenital athymia in complete DiGeorge Anomaly, a fatal paediatric disorder.

The investigational candidate has FDA breakthrough therapy, rare paediatric disease, regenerative medicine advanced therapy (RMAT) and orphan drug designations.

Sinovant also announced it has formed an alliance with Renexxion to obtain the Chinese rights for an investigational gastrointestinal prokinetic called naronapride.

Initially, Sinovant intends to develop naronapride for the treatment of irritable bowel syndrome with constipation (IBS-C) and then plans to extend into other gastrointestinal conditions.

Furthermore, Sinovant has collaborated with a public health non-profit organisation China Liver Health to boost the availability of new medicines for liver and infectious diseases in the country.